| INTRODUCTION
The clinical courses of inflammatory bowel diseases (IBD) differ widely, with some individuals having only mild symptoms, without significant morbidity and others suffering from severe life-threatening conditions, necessitating intense management including surgery.
Identification of reliable predictors for IBD severity is an unmet clinical need and an ongoing challenge in gastroenterology.
Environmental influences can trigger and shape gut inflammation, and effects of smoking, 1 diet, 2 physical activity, 3 exposure to high altitudes 4 and drugs 5 on IBD disease course have been demonstrated. In addition, there is compelling evidence that genetic factors contribute to gut inflammation, and concordance of IBD phenotypes within families has been noted. 6 To date, 240 individual genetic loci have been associated with an increased IBD risk. 7 However, in a systematic analysis, most genetic polymorphisms did not independently predict IBD disease course. 8 Understanding the course of IBD likely requires the integration of genetic and environmental influences. Some environmental effects will be limited to subgroups of patients with certain genetic backgrounds and vice versa; genetic associations might be overlooked if relevant environmental factors are not considered. The complexity of assessing gene-environment interactions for IBD pathogenesis is challenging and to the best of our knowledge, no examples have been reported. 9 Effects of smoking on IBD are strong and well characterised and therefore, gene-environment interactions might be easier detectable for smoking than for any other environmental risk factor. The effect of smoking in Crohn's disease (CD) and ulcerative colitis (UC) is differential. 10 In Crohn's disease, smoking generally aggravates the disease course, [11] [12] [13] conferring higher need for immunosuppression, 14 higher risk of intestinal resection, 15 increased recurrence rates 14, 16 despite efficient medical treatment 15 and reduced quality of life. 17 In contrast, smoking seems to protect from subsequent development of UC. 18 The risk of UC in former smokers is higher compared to patients who never smoked, 19, 20 and a less severe disease course is observed upon resumption of smoking. 19, 20 Twin studies have demonstrated that in siblings with a similar genetic risk for IBD but discordant smoking status, Crohn's disease developed in the smoker and ulcerative colitis in the nonsmoker. 21 The reasons for this have not been clarified.
Nicotine dependency has a strong hereditary compound 22 and genetics determine several independent aspects of smoking behaviour. The strongest genetic effects have been observed for smoking quantity. [23] [24] [25] Genome-wide association studies have discovered high-risk single nucleotide polymorphisms (SNPs) close to nicotinic acetylcholine receptor (nAChR) subunits. Additional risk areas were observed for CYP2A6, associated with nicotine degradation. [23] [24] [25] Individual SNPs associated with smoking quantity have been combined to a genetic risk score that predicts smoking quantity. 26 It is important to emphasise that SNPs associated with smoking quantity do not necessarily convey a risk of ever-smoking. Ever-smoking status is an independent phenotype associated with separate SNPs including a valine-to-methionine substitution in the brain-derived neurotrophic factor gene. 23 Smoking is a complex behaviour. Genetic signals for smoking quantity contribute to the number of cigarettes per day. [23] [24] [25] However, the genetic effects go beyond cigarettes per day, and SNPs correlate with patient cotinine as well as carbon monoxide levels in expiratory air even after correction for cigarettes per day. 27 Therefore, genetics may predict "smoking topography" including length and depth of inhalation and number of puffs per cigarette, the combination of which will ultimately determine the total exposure towards nicotine and other toxins. 
| Ethical considerations
The IBD cohort study has been approved by the ethics committees of Zurich country (EK-1316). All patients signed an informed consent and confirmed their participation in the cohort study at the time of enrolment and gave informed consent for data collection and analysis for research purposes. The current sub-study has been evaluated and approved by the scientific board of SIBDC.
| DNA genotyping and SNP selection
Genotyping of SIBDCS patients was performed on patient samples using MALDI-TOFF mass spectrometry-based SNP genotyping. 28 All
SNPs that influence cigarette consumption or nicotine addiction with genome-wide significance from 3 genome-wide association studies and an independent meta-analysis were selected. [23] [24] [25] 29 Figure S1 and DataS1: Table S1 ). Hardy-Weinberg equilibrium was assessed but not expected for our study cohort, which constitutes a nonrandom sample from the Swiss population.
To control for any potential population structure in our SNPs,
we performed principle component analysis on our SNPs (post linkage disequilibrium-filtering) and considered the first 3 components as covariates 30 ( Figure S2 ).
| Genetic risk score and additional SNPs
To conservatively combine genetic information, we followed a validated approach. 26 We combined all 6 SNPs associated with smoking quantity (rs588765, rs1329650, rs1051730, rs6474412, rs4105144
and rs3733829) to a smoking quantity-associated genetic risk score 
| Statistical analysis
The 2 alleles of a given SNP were considered to act in a log-additive manner (ie each risk alleles would have an additive effect); rs6265 was assumed to act co-dominant (ie each genetic variant is allowed its own effect). We selected these genetic models as they best explained the variation in smoking using the Akaike information criterion (AIC), which is a measure for the goodness-of-fit of a given model with a preference for models with a lower number of parameters.
For the multivariate analysis, we built a separate model for each To assess internal validity of our model for intestinal surgery in
Crohn's disease patients, we generated 500 bootstrap samples from our Crohn's disease patient cohort and fit our final intestinal surgery model on each of these samples. We derived empirical confidence intervals for the distribution of our estimated model coefficients as a post hoc robustness analysis. 31 All analyses were performed in R version 3.3.0 (2016-05-03).
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| Study population and genetic information
For our analysis, data from 1434 individuals (821 CD, 613 UC) were available. Our cohort comprises a mixed patient population of IBD patients with mild to severe disease (Table 1) . Seventeen smoking behaviour-associated SNPs across 8 genes were considered; after exclusion of SNPs in strong linkage disequilibrium (ie strong genotypic correlation), 8 SNPs across 7 genes remained for further analysis ( Figure S1 , Data S1: Table S1 ).
| Risk of smoking in IBD patients
A total of 594 patients in our cohort (42%) were smokers at time of diagnosis. In a model including both Crohn's disease and UC patients, we noted significantly lower smoking rates in UC patients, old age or very young age at diagnosis, patients born more recently, patients who were married, Caucasian patients, those with higher levels of physical activity, better education and low alcohol consumption ( Figure S3 , Data S1). CD: ≥9 surgical procedures; n (%)
Ulcerative colitis disease characteristics and treatment history IQR, interquartile range; CD, Crohn's disease; UC, Ulcerative colitis; HADS, hospital anxiety and depression scale; SNP, single nucleotide polymorphism.
Our genetic risk score interacted with sex: a high genetic risk score was associated with an increased prevalence of smoking in females, but was not associated with smoking in males ( Figure S3 ).
| Rates of smoking cessation in IBD patients
In our cohort, 737 out of 1434 (57.4%) patients were recorded as ever-smoking. Of these ever-smokers, 313 were found to be nonsmoking as of their last follow-up. Our genetic risk score also interacted with sex for the prediction of smoking cessation: We noted significantly lower rates of smoking cessation in females with high genetic risk score status but not in males (Data S1).
3.4 | A genetic risk score to predict surgery in
Crohn's disease patients who smoke
In our cohort, 435 out of 821 Crohn's disease patients (52.9%) had surgery of the colon or small intestine. Frequently, more than 1 surgery was performed (median number of procedures in operated patients: 2, range: 0-9, Table 1 ). Strong predictors for number of surgeries include disease duration, year of IBD diagnosis ( Figure S4 ), ileal disease location, fistula, low physical activity, female sex and rare-drinker status ( Table 2 , Data S1: Table S4 ).
We found significant and large effects of our genetic risk score in smoking patients on the number of surgeries ( Figures 1A and 2 ).
For smoking individuals, rates of surgery are predicted to increase by 21%, 95% confidence interval: 12%-35%, per risk allele, holding all other variables constant (P<.001 after Bonferroni correction).
This translates to a predicted 3.5-fold (95% confidence interval:
2.42-to 5.71-fold) higher number of surgical procedures in smokers with 12 risk alleles than individuals with the lowest risk (0 alleles, Figure 1B ).
In order to assess internal validity of our model, we generated 500 bootstrap samples from our Crohn's disease patient data and fit our model to these bootstraps. Our empirical bootstrap estimates for the interaction between smoking and genetic risk score for the prediction of intestinal surgery rates was found to be robust to bootstrapping (95% confidence interval: 10%-33%, Figure S5 ). To further validate our model, 100 repeats of 5-fold cross-validation were performed. In 5-fold cross-validation, 80% of the data are used for training of a model and the utility of the model for predicting the phenotype of the remaining data not used for fitting of the model is assessed. We found that inclusion of our genetic risk score increased the performance of our model in the unseen test data in comparison to a model without our genetic risk sum (Figure S5 B) .
In an analysis for each SNP separately, rs588765, rs1051730 and (but not rs1329650), significant effects were also detected in a univariate analysis ( Figure 1C-E) .
A post hoc analysis revealed that out of 6 SNPs of our genetic risk score, only 2 SNPs substantially improved the fit of the model ( Figure S6 ). The strongest contributions were derived from rs588765
(nAChR) and rs1329650 (Sec13) whose effects were nearly additive.
We summarised these 2 SNPs to a simplified risk score, which A predictive model is provided for the number of intestinal surgeries in Crohn's disease patients (top) and for colectomy in ulcerative colitis patients (bottom) with significant predictors indicated. The complete models are provided in Data S1 (Table S4 and S6). Included covariates were determined through a step-wise model selection using Akaike information criterion (AIC) as criteria.
a Indicates Bonferroni-corrected P-value <.05. Low [1, 7] High [8, 12] *** *** 
(C) (D) (E) (F)
Smoking status at diagnosis resulted in a 60% (95% confidence interval: 38%-100%, P<.00001) increase per risk allele and a predicted 4.1-fold (95% confidence interval: 3.01-5.6-fold) increase in the rates of surgery when smokers in the highest and lowest risk-groups were compared ( Figures 1F, 2) .
Interestingly, a different subset of the 6 SNPs contributed to the prediction of smoking ( Figure S3D ).
| Sensitivity of our genetic risk score effects to definition of smoking status
The interaction of genetic risk with smoking for the prediction of surgery remains robust upon variation of our definition of smoking.
When ever-smoking status was considered rather of smoking status at diagnosis, the interaction of a high genetic risk score status with smoking for the prediction of intestinal surgery remains significant in a fully corrected model similar to Table 2 (P = .024). Similarly, if individuals who started smoking after inclusion into the study or quit smoking during the study were excluded, the association between the genetic risk score and surgery frequency in smokers remained intact (P = .0017 and P = .0004 respectively). Finally, when restricting the analysis to persistent smoker and persistent nonsmokers, the interaction between smoking and a high genetic risk score for prediction of surgery remained significant (P = .01). Table S6 ).
The genetic risk score was not associated with lower risk of surgical procedures in smokers, neither nominally nor in a multivariate analysis ( Figure 1B , lower bars, Table 2 ). Among the 153 smoking UC patients, comparing the subgroup with low genetic risk (1-7 alleles) and high genetic risk (8-12 alleles) , the rate of surgery was 1.2-fold higher in the low-risk group compared to the high-risk group (14% vs 12%, n.s.).
| Effects of smoking behaviour-associated SNPs on disease location in Crohn's disease
Smoking increased the risk of ileal disease in IBD patients ( Figure 4A ). SNP rs6265-TT was associated with a lower likelihood of ileal disease; smoking modified this effect and Crohn's disease patients who did not smoke carrying the TT allele had the lowest risk of ileal involvement (Figure 4 A, DataS1: Table S7 ). The interaction of rs6265 with smoking remained significant in a multivariate analysis (Data S1: Table S7 ) but not after Bonferroni correction. No association of the genetic risk score with ileal disease location in smokers was found. In a separate analysis, no significant interaction of smoking, any SNP tested or our genetic risk score with fistulising disease in Crohn's disease patients was found (P = .34 for interaction of the genetic risk score with smoking for prediction of fistula).
| Effects of rs6265 on the extent of disease in UC patients
Earlier diagnosis, younger age at diagnosis and female sex all were associated with left-sided colitis or pancolitis vs proctitis. Interestingly, rs6265, but not our genetic risk score, interacted significantly with smoking for extension of disease ( Figure 4B , Data S1).
| DISCUSSION
Understanding and predicting the clinical course of IBD remains an unmet challenge requiring a clear understanding of genetic and environmental effects. This study demonstrates that the presence of smoking quantity-associated SNPs is associated with a more severe disease course in Crohn's disease patients who smoke. Thus, interactions of genotype and environment are identified using smoking as a well-established environmental factor in IBD.
We propose a genetic risk score, which includes 6 SNPs from 4 genetic regions identified in genome-wide association studies due to modification of smoking quantity. The nicotinic acetylcholine receptor plays a central role in nicotine addiction and is associated with 3 SNPs investigated in our study (rs588765, rs1051730 and rs6474412). [23] [24] [25] Other SNPs (rs4105144 and rs3733829) are related to the nicotine-degrading enzyme CYP2A6. Individual rates for nicotine breakdown vary considerably 33 and rapid nicotine clearance is a risk for nicotine dependence. However, rs3733829 has also been proposed to act independently from CYP2A6. 27, 34 Finally, for rs1329650, situated within an intergenic region on chromosome 10 (LOC100188947, in the neighbourhood of the Sec13 gene), mechanistic details are unclear.
By definition, all SNPs have been associated with smoking quantity in genome-wide association studies. Individual SNPs were also shown to promote higher cotinine 35 and carbon monoxide levels 27 and nicotine dependence. 36, 37 These SNPs may be regarded as a proxy for exposure to nicotine and tobacco in patients.
We used number of surgeries in Crohn's disease patients as a surrogate outcome measure for a severe disease course and tested whether risk alleles of smoking behaviour-associated SNPs would interact with the environmental risk factor of smoking. When looking at individual SNPs, the strongest effects were observed for 2 (1) (2) (3) (4) (5) (6) (7) High genetic risk (7) (8) (9) (10) (11) (12) Non-smoker at Smoker at diagnosis diagnosis Table S5) number of surgical procedures for high-risk individuals was up to 3.7-fold higher ( Figure 1B) . We also noted paradoxical (ie protective) effects of a high genetic risk score in nonsmokers which was robust to multiple-test correction in our multivariate analysis ( Figure 1B) .
However, the reasons and the relevance of these effects (if any) remain unclear.
For the prediction of the surgery outcome, a model with a simplified genetic risk score of only 2 SNPs worked slightly better than our original risk score. Therefore, genetic effects on smoking quantity seem to be redundant or satiable in a manner not understood.
In a conservative approach, we preferred using the genetic risk score as a potentially robust predictor for smoking quantity following a published approach 26 but further inquiry seems necessary.
Smoking quantity-associated SNPs modify patient behaviour to increase nicotine and toxin exposure. Carriers of risk alleles had a higher risk of smoking complications including lung cancer, [38] [39] [40] 45 and lower rates of knee replacements. 46 In line with our study, odds ratio of 1.1-1.9 per risk allele were observed. However, predicted odds ratio increased to ≥2 if more than 1 genetic region was considered. 37, 47 Effects of smoking behaviour-associated SNPs are an example of genetically determined human behaviour subsequently aggravating a disease. In humans, nicotine exposure cannot be studied in randomised trials but random distribution of smoking quantity-associated SNPs in patients provides a natural randomisation (Mendelian randomisation study). For Crohn's disease, the number of surgeries and by extension, the risk for a more severe disease course seems directly related to the dosage of tobacco smoke the patient has been exposed to.
In UC, we found no association between genetic risk and surgery risk in smokers. Our study might be underpowered as a post hoc power analysis revealed only 26% power to detect a 50% decrease in surgery rates (not shown). However, our results are in line with a recent metaanalysis which did not find beneficial effects of smoking in UC. 48 Similarly, we detected no association of smoking quantity-associated SNPs with occurrence of fistula. Our study was well-powered (97.8%) for detection of a 2-fold effect of genetic risk in smokers.
While our results do not rule out smoking as a risk factor for fistula, our findings argue against strong dose-dependent effects of tobacco and nicotine, in agreement with a previous small clinical study. 49 We found significant interactions of rs6265 with ileal disease location in Crohn's disease. Effects of the T allele of rs6265 might be subsumed as destabilising human emotions and behaviour: Individuals with rs6265-T are strongly affected by negative social stress, 50 more likely to be suicidal, 51 and also showed greater intrinsic motivation during exercise. 52 In genome-wide association studies, rs6265-T was associated with a lower lifetime risk of ever-smoking 23 but not smoking quantity. On the other hand, smokers carrying the rs6265-T allele were shown to start smoking at a younger age. 53 The association of rs6265-T with ileal disease location might therefore be due to earlier smoking in our rs6265-T patients, triggering and shaping an immunological response at a vulnerable age. Interestingly, rs6265-T enhanced protective effects of smoking in melanoma 44 and increased the risk of childhood asthma. 54 Several lines of evidence also indicate a direct role of brain-derived neurotrophic factor (BDNF) on the immune and nervous system of the gut. 55 The impact of brain-derived neurotrophic factor on IBD clearly warrants further study. The results of this study have practical implications: Crohn's disease patients who smoke are at higher risk for surgery and a high genetic risk in smoking-associated SNPs makes adverse outcomes in smokers much more likely. A high-risk score might thus trigger more intense IBD treatment and more intense measures towards achievement of smoking cessation. 48 Genetic markers have several advantages compared to number of cigarettes per day. In contrast to cigarettes per day, genetic markers do not change during the lifetime of an individual. Additionally, they are available from a simple blood sample as well as independent from biases in patient reporting or physician recording. Future treatment algorithms might integrate this genetic information for decision-making.
Our study has several strengths. Although previous studies leveraged smoking and genetic information to control for genetic differences, our study uses this data to assess the differential effect of smoking given a certain genetic makeup. 21 Furthermore, the prospective assessment of well-characterised patients allowed us to control for many potential confounders. Bootstrap confidence intervals and repeated 5-fold cross-validation indicate that our main findings are internally valid and that our model is not overly biased for prediction on new data. However, while robust statistical effects for our risk score were observed, findings for disease location in Crohn's disease were much weaker and did not remain significant after Bonferroni correction. In addition, validated questionnaires for nicotine dependence or biomarkers for nicotine consumption such as cotinine are not available within the SIBDCS data set. As such, though there is an extensive body of literature supporting the association of these smoking quantity-associated SNPs with variables other than number of cigarettes per day [23] [24] [25] : patient cotinine 56, 57 and carbon monoxide 27 levels and nicotine dependence. 36, 37, [58] [59] [60] However, without these data we cannot distinguish, whether the interaction of genetic risk with smoking in IBD patients is mediated via the number of cigarettes per day or in addition via a different smoking topography (ie deeper inhalation, number of puffs per cigarette).
In summary, we describe a genetic risk score for predicting the risk of surgery in Crohn's disease patients who smoke. This score might help select high-risk smokers for further intense management.
Our study provides a clear example of an interaction between an individual's genome and environment for determination of the severity of Crohn's disease.
